Iovance Biotherapeutics (IOVA)
NASDAQ:IOVA
Want to see IOVA full AI Analyst Report?
IOVA Stock Chart & Stats
$3.86
-$0.33(-4.53%)
At close: 4:00 PM EST
$3.86
-$0.33(-4.53%)
Day’s Range― - ―
52-Week Range$1.66 - $5.63
Previous CloseN/A
Volume2.95M
Average Volume (3M)14.50M
Market Cap
$1.88B
Enterprise Value$1.26B
Total Cash (Recent Filing)$313.44M
Total Debt (Recent Filing)$47.78M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Aug 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding446,502,400
10 Day Avg. Volume13,013,578
30 Day Avg. Volume14,496,381
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.40
Price to Sales (P/S)3.70
P/FCF Ratio-2.90
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue4.40
Enterprise Value/Gross Profit3.84
Enterprise Value/Ebitda-3.91
Forecast
1Y Price Target
$9.80Price Target Upside153.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$361.99M
Bulls Say, Bears Say
Bulls Say
Commercial Momentum & GuidanceSustained, high-single-quarter revenue growth and explicit full-year guidance signal durable commercial traction for AMTAGVI. Strong Q1 sales and firm 2026 targets reflect expanding physician awareness and adoption that should support revenue scaling and predictable operations over the next 2–6 months.
In‑house Manufacturing ControlRestoring and owning manufacturing capacity materially reduces supply risk and gives Iovance control over throughput, quality and scale economics. This supports margin improvement potential, smoother patient deliveries, and easier international rollouts—structural advantages for commercial durability.
Balance Sheet & Runway ExtensionManagement’s stated cash balance and runway into 2028, together with reduced R&D spend, provide multi-quarter funding visibility. Combined with low reported leverage, this gives the company the financial flexibility to scale commercial operations and pursue registrational milestones without immediate refinancing pressure.
Bears Say
Heavy Cash BurnPersistent, large negative operating and free cash flows indicate the business consumes substantial liquidity as it commercializes. That continuing cash burn forces reliance on external financing or share issuances, constrains discretionary investment, and raises execution risk if revenue growth lags expectations.
Large Ongoing Net LossesSubstantial trailing net losses and depressed operating margins show the company remains far from profitability. Until fixed costs are absorbed by higher volumes and per‑patient economics improve, negative returns will erode equity value and limit the company’s ability to self-fund growth.
Capital Structure / Dilution RiskExpanded authorized shares and prior ATM usage create a durable overhang: while improving fundraising flexibility, the change raises the probability of future dilution. For a cash‑consuming biotech, this structural financing option can pressure per‑share economics and investor returns over time.
Iovance Biotherapeutics News
IOVA FAQ
What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest stock price was $1.66 and its highest was $5.63 in the past 12 months.
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is $1.88B.
When is Iovance Biotherapeutics’s upcoming earnings report date?
Iovance Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 40 days.
How were Iovance Biotherapeutics’s earnings last quarter?
Iovance Biotherapeutics released its earnings results on May 07, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.154 by -$0.036.
Is Iovance Biotherapeutics overvalued?
According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued.
Does Iovance Biotherapeutics pay dividends?
Iovance Biotherapeutics does not currently pay dividends.
What is Iovance Biotherapeutics’s EPS estimate?
Iovance Biotherapeutics’s EPS estimate is -0.13.
How many shares outstanding does Iovance Biotherapeutics have?
Iovance Biotherapeutics has 446,502,400 shares outstanding.
What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
Iovance Biotherapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.154. Following the earnings report the stock price went down -13.203%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics?
Currently, no hedge funds are holding shares in IOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.80 (153.89% Upside)
$9.80 (153.89% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 571.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.51%
12-Months-Change
Fundamentals
Return on Equity
-50.17%
Trailing 12-Months
Asset Growth
-4.25%
Trailing 12-Months
Company Description
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
IOVA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful operational progress: high single-quarter revenue growth (~45% YoY), robust Amtagvi demand (+38% YoY), tighter Q2/full-year guidance, expanded manufacturing control, R&D cost reductions, extended cash runway into 2028, and encouraging early clinical signals (e.g., 40% ORR in serous endometrial cancer). Near-term headwinds include a one-time facility-related margin hit (Q1 gross margin ~41%), some quarter-to-quarter revenue volatility in Proleukin, continued use of ATM financing, and the usual clinical/regulatory and enrollment execution risks. Overall, the positives—notably accelerating commercial traction, pipeline advances, and improved cost discipline—substantially outweigh the listed challenges.View all IOVA earnings summariesIOVA Stock 12 Month Forecast
Average Price Target
$9.80
▲(153.89% Upside)
Technical Analysis
Ownership Overview
0.32% Insiders
12.55% Mutual Funds
15.99% Other Institutional Investors
55.16% Public Companies and Individual Investors